Sökning: WFRF:(Ose J.)
> (2000-2004) >
Cerivastatin gender...
Cerivastatin gender effect : Sub-analyses of results from a multinational, randomised, double-blind study
-
- Ose, L (författare)
- Univ Oslo, Rikshosp, Dept Med, Lipid Clin, N-0027 Oslo, Norway Laakariasema Koe Oy, FIN-00100 Helsinki, Finland Seinajoki Hlth Ctr, FIN-60220 Seinajoki, Finland Univ Sjukhuset, Med Kliniken, S-58185 Linkoping, Sweden Uppsala Univ, Dept Geriatr, S-75125 Uppsala, Sweden Sahlgrenska Sjukhuset, Med Kliniken, S-41345 Gothenburg, Sweden
-
- Luurila, O (författare)
- Univ Oslo, Rikshosp, Dept Med, Lipid Clin, N-0027 Oslo, Norway Laakariasema Koe Oy, FIN-00100 Helsinki, Finland Seinajoki Hlth Ctr, FIN-60220 Seinajoki, Finland Univ Sjukhuset, Med Kliniken, S-58185 Linkoping, Sweden Uppsala Univ, Dept Geriatr, S-75125 Uppsala, Sweden Sahlgrenska Sjukhuset, Med Kliniken, S-41345 Gothenburg, Sweden
-
Eriksson, J (författare)
-
visa fler...
-
- Olsson, Anders (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Internmedicin,Endokrin- och magtarmmedicinska kliniken US
-
- Lithell, H (författare)
- Univ Oslo, Rikshosp, Dept Med, Lipid Clin, N-0027 Oslo, Norway Laakariasema Koe Oy, FIN-00100 Helsinki, Finland Seinajoki Hlth Ctr, FIN-60220 Seinajoki, Finland Univ Sjukhuset, Med Kliniken, S-58185 Linkoping, Sweden Uppsala Univ, Dept Geriatr, S-75125 Uppsala, Sweden Sahlgrenska Sjukhuset, Med Kliniken, S-41345 Gothenburg, Sweden
-
- Widgren, B (författare)
- Univ Oslo, Rikshosp, Dept Med, Lipid Clin, N-0027 Oslo, Norway Laakariasema Koe Oy, FIN-00100 Helsinki, Finland Seinajoki Hlth Ctr, FIN-60220 Seinajoki, Finland Univ Sjukhuset, Med Kliniken, S-58185 Linkoping, Sweden Uppsala Univ, Dept Geriatr, S-75125 Uppsala, Sweden Sahlgrenska Sjukhuset, Med Kliniken, S-41345 Gothenburg, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2000
- 2000
- Engelska.
-
Ingår i: Current Medical Research and Opinion. - 0300-7995 .- 1473-4877. ; 16:2, s. 80-87
- Relaterad länk:
-
https://urn.kb.se/re...
Abstract
Ämnesord
Stäng
- We previously reported the results of a multicentre, randomised, double-blind, parallel-group study comparing the efficacy, and safety of cerivastatin 0.4 mg/day and cerivastatin 0.2 mg/day in patients with primary hypercholesterolaemia. Exploratory analysis in this study suggested a gender difference ill the 0.4 wry group: mean low-density lipoprotein cholesterol (LDL-C) decreased by 44.4 +/- 8.9% in women, compared with a mean decrease of 37.0 +/- 0.9% in men (p < 0.046). This paper reports the results of further sub-analyses from this study. Overall in the per-protocol (PP) population. 71.5% (n = 73) of women taking cerivastatin 0.4 mg had all LDL-C decrease of > 40%, compared with 38.0% (n = 76) of men taking the same dose. In the cerivastatin 0.2 mg PP population, 34% (n = 17) of women had an LDL-C decrease of > 40%, compared with 19% (n = Ig) of men. Mean LDL-C/HDL-C ratio decreased by 43% from baseline to the end of the study in the cerivastatin 0.4 mg PP group: -41.3% in males la. -48.3% in females. In the cerivastatin 0.2 mg group, the decrease in LDL-C/HDL-C ratio from baseline to endpoint did not markedly differ between genders: -37.0% for males vs. -37.3% for females. Categorial analysis of the LDL-C/HDL-C ratio found that 90% of PP patients taking cerivastatin 0.4 mg, and 84% of PP patients taking cerivastatin 0.2 my, had a low CHD risk (defined as a LDL-C/HDL-C ratio less than or equal to 3) after 8 weeks of treatment. The 6th and 95th percentiles of the distribution of LDL-C reduction from baseline revealed that 90% of PP patients taking cerivastatin 0.4 mg had all LDL-C reduction of between 22% and 56%. The mean LDL-C reduction for this 90% subset of patients uas 40.1%. The same analysis for PP patients taking cerivastatin 0.2 my found that 90% had all LDL-C reduction of between 13% and 49%. The mean LDL-C reduction in this 90% subset of patients was 31.5%. Of the patients raking cerivastatin 0.4 mg and valid for treatment according to National Cholesterol( Education Program (NCEP) criteria, 71% (149/211) achieved NCEP targets for LDL-C at Week 16.
Nyckelord
- cerivastatin
- efficacy
- gender
- hypercholesterolaemia
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas